Synonyms: 3,4-dihydroxy-L-phenylalanine | Inbrija® (levodopa inhalation powder) | L-DOPA | Sinemet®
levodopa is an approved drug (FDA (1993), EMA (2003))
Compound class:
Metabolite or derivative
Comment: L-DOPA is the precursor to the neurotransmitters dopamine collectively known as catecholamines. Used in the treatment of Parkisons disease. Note a deuterated derivative D3 L-DOPA with enhanced properties is under development.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: levodopa |
|
No information available. |
Summary of Clinical Use |
Used in the treatment of Parkinson's disease. The 2003 EMA approval authorises the use of levodopa in a fixed-dose combination with carbidopa and entacapone (called Stalevo®). The EMA has also approved a combination containing just levodopa and carbidopa (Numient®, 2015). |
External links |
For extended ADME data see the following: European Medicines Agency (EMA) |